Adverse Drug Reaction Classification System

ADR Ontology
ADR Term Extrapyramidal disorder
ADR ID BADD_A01568
ADR Hierarchy
17      Nervous system disorders
17.01      Movement disorders (incl parkinsonism)
17.01.02      Dyskinesias and movement disorders NEC
17.01.02.007      Extrapyramidal disorder
Description A disorder characterized by abnormal, repetitive, involuntary muscle movements, frenzied speech and extreme restlessness. [CTCAE] Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA. [MeSH]
MedDRA Code 10015832
MeSH ID D001480
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE)
Synonym
Benign shuddering attacks | Drug-induced extrapyramidal side effects | Extrapyramidal disorder | Extrapyramidal disorder (NOS) | Extrapyramidal disorder NEC | Extrapyramidal symptoms | Extrapyramidal syndrome | Extrapyramidal syndrome (NOS) | Other and unspecified extrapyramidal diseases and abnormal movement disorders | Other extrapyramidal disease and abnormal movement disorders | Other extrapyramidal diseases and abnormal movement disorders | Syndrome extrapyramidal | Unspecified extrapyramidal disease and abnormal movement disorder | Extrapyramidal disorder aggravate | Extrapyramidal disorder aggravated | Basal Ganglia Diseases | Basal Ganglia Disease | Basal Ganglia Disorders | Basal Ganglia Disorder | Extrapyramidal Disorders | Extrapyramidal Disorder | Lenticulostriate Disorders | Lenticulostriate Disorder
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D01318Lorazepam0.000176%
BADD_D01326Loxapine--
BADD_D01330Lurasidone0.009674%
BADD_D01350Maprotiline--
BADD_D01351Maprotiline hydrochloride--
BADD_D01378Memantine--
BADD_D01379Memantine hydrochloride--
BADD_D01405Methadone0.001193%
BADD_D01442Metoclopramide0.160345%
BADD_D01451Metyrosine--
BADD_D01465Miglustat0.006469%
BADD_D01476Mirtazapine0.000360%
BADD_D01487Molindone--
BADD_D01488Molindone hydrochloride--
BADD_D01588Nortriptyline--
BADD_D01589Nortriptyline hydrochloride--
BADD_D01598Ofloxacin--
BADD_D01599Olanzapine0.010967%
BADD_D01600Olanzapine pamoate--
BADD_D01617Ondansetron0.000021%
BADD_D01637Oxcarbazepine--
BADD_D01656Paliperidone0.325363%
BADD_D01657Paliperidone palmitate--
BADD_D01679Paroxetine0.000043%
BADD_D01680Paroxetine hydrochloride--
BADD_D01681Paroxetine hydrochloride hemihydrate--
BADD_D01682Paroxetine impurity a--
BADD_D01683Paroxetine mesylate--
BADD_D01735Pergolide--
BADD_D01736Pergolide mesylate--
The 4th Page    First    Pre   4 5 6    Next   Last    Total 6 Pages
ADReCS-Target
ADR Term Drug Name Target